JP6133790B2 - ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 - Google Patents

ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 Download PDF

Info

Publication number
JP6133790B2
JP6133790B2 JP2013554652A JP2013554652A JP6133790B2 JP 6133790 B2 JP6133790 B2 JP 6133790B2 JP 2013554652 A JP2013554652 A JP 2013554652A JP 2013554652 A JP2013554652 A JP 2013554652A JP 6133790 B2 JP6133790 B2 JP 6133790B2
Authority
JP
Japan
Prior art keywords
benztropine
pharmaceutical composition
disease
immunomodulator
receptor modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013554652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506583A5 (https=
JP2014506583A (ja
Inventor
ピーター シュルツ
ピーター シュルツ
ルーク レアソン
ルーク レアソン
ヴィシャル デシュムク
ヴィシャル デシュムク
コスタス ライジオティス
コスタス ライジオティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of JP2014506583A publication Critical patent/JP2014506583A/ja
Publication of JP2014506583A5 publication Critical patent/JP2014506583A5/ja
Application granted granted Critical
Publication of JP6133790B2 publication Critical patent/JP6133790B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2013554652A 2011-02-18 2012-02-17 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 Expired - Fee Related JP6133790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161444666P 2011-02-18 2011-02-18
US61/444,666 2011-02-18
PCT/US2012/025712 WO2012112933A1 (en) 2011-02-18 2012-02-17 Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017026806A Division JP2017132769A (ja) 2011-02-18 2017-02-16 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Publications (3)

Publication Number Publication Date
JP2014506583A JP2014506583A (ja) 2014-03-17
JP2014506583A5 JP2014506583A5 (https=) 2015-04-09
JP6133790B2 true JP6133790B2 (ja) 2017-05-24

Family

ID=46672968

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013554652A Expired - Fee Related JP6133790B2 (ja) 2011-02-18 2012-02-17 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
JP2017026806A Pending JP2017132769A (ja) 2011-02-18 2017-02-16 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
JP2019211952A Pending JP2020040981A (ja) 2011-02-18 2019-11-25 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017026806A Pending JP2017132769A (ja) 2011-02-18 2017-02-16 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
JP2019211952A Pending JP2020040981A (ja) 2011-02-18 2019-11-25 ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Country Status (6)

Country Link
US (4) US9592288B2 (https=)
EP (2) EP2675893B1 (https=)
JP (3) JP6133790B2 (https=)
DK (1) DK2675893T3 (https=)
ES (1) ES2716865T3 (https=)
WO (1) WO2012112933A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017132769A (ja) * 2011-02-18 2017-08-03 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838486A1 (en) * 2011-08-07 2013-02-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
EP2724723A1 (en) * 2012-10-25 2014-04-30 Universitätsklinikum Hamburg-Eppendorf Tegaserod for use in the treatment of nerve injuries
DK2943189T3 (da) * 2013-01-08 2021-04-06 Pathologica Llc Mitoguazon til behandling af progressiv multipel sklerose
WO2014138298A1 (en) * 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
CA3212170A1 (en) * 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20170027957A1 (en) * 2013-12-20 2017-02-02 University Of Manitoba Methods and compositions for treatment of peripheral neuropathies
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
EP3118621A1 (en) * 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
PT3344248T (pt) * 2015-09-02 2022-06-29 Trevena Inc Compostos moduladores do recetor opioide delta contendo aza-heterocíclicos de 6 membros, composições compreendendo os mesmos e seus usos
CN107286031B (zh) * 2016-04-05 2019-08-09 上海医药工业研究院 2-二乙氨基-1-甲基乙基-7-环己基-7-氧庚酸酯的制备方法
JP2019535265A (ja) * 2016-11-14 2019-12-12 メモリアル スローン ケタリング キャンサー センター 幹細胞由来シュワン細胞
US11225487B2 (en) 2017-02-17 2022-01-18 Trevena, Inc. 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
BR112019016827A2 (pt) 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
EP3609511B1 (en) * 2017-04-13 2025-11-26 The Board of Trustees of the Leland Stanford Junior University Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
US11478467B2 (en) * 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3412294A1 (en) * 2017-06-08 2018-12-12 Universite De Fribourg Hdac1/2 activator for promoting and/or accelerating myelination and/or remyelination
WO2019172969A1 (en) * 2018-03-08 2019-09-12 The Scripps Research Institute Methods for promoting myelination and for treating demyelinating diseases
US20210015813A1 (en) 2018-03-08 2021-01-21 Victoria Link Ltd. Treatment of demyelinating diseases
JP2021520362A (ja) * 2018-04-05 2021-08-19 フリークエンシー セラピューティクス インコーポレイテッド 再ミエリン化を増加させるための組成物および方法
JP2021521189A (ja) * 2018-04-13 2021-08-26 モデハイ シェヴィオンCHEVION, Mordechai 脱髄の治療のための組成物及び方法
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
JP2021527712A (ja) * 2018-06-14 2021-10-14 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を、診断、監視、および治療するための方法
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
CN111317754B (zh) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 一种北豆根总碱的制备方法及应用
CN109942592B (zh) * 2019-05-09 2020-07-14 江西中医药大学 一种新原阿片碱型生物碱及其制备方法和应用
EP3797769A1 (fr) * 2019-09-25 2021-03-31 Fontès, M. Michel Composition a usage therapeutique
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
CN114793420A (zh) * 2020-01-22 2022-07-26 抗菌技术生物技术研究与发展股份有限公司 用于治疗脊髓损伤和改善运动功能的依来曲普坦氢溴酸盐
US20230167406A1 (en) * 2020-05-01 2023-06-01 The Children's Medical Center Corporation Compositions and methods of promoting myelination
CA3219716A1 (en) * 2021-05-21 2022-11-24 Wen Zeng Method for modulating neuropathies
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
AU2023231903A1 (en) 2022-03-11 2024-09-19 Teijin Pharma Limited Medicine containing vitamin d derivative or pharmaceutically acceptable salt or solvate thereof, used in combination with immunomodulatory substance
WO2023225206A1 (en) 2022-05-18 2023-11-23 The Scripps Research Institute Method for enhancing remyelination via co-administration of muscarinic receptor antagonists and vitamin d analogues
CN116115760A (zh) * 2022-12-15 2023-05-16 浙江大学 Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
WO2025049588A1 (en) * 2023-08-29 2025-03-06 The Trustees Of Indiana University Novel treatments for optic neuropathies and glaucoma
CN117599054B (zh) * 2024-01-24 2024-03-29 成都第一制药有限公司 一种治疗假性近视的药物组合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP0584185B1 (en) 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
JPH10218867A (ja) 1997-02-10 1998-08-18 Pola Chem Ind Inc ドーパミン再取り込み阻害剤
CA2301883A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP2002519373A (ja) * 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
BR9914251A (pt) 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2792527B1 (fr) 1999-04-22 2004-08-13 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
PT1207860E (pt) 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2001047501A1 (en) 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
JP2004501147A (ja) 2000-06-20 2004-01-15 アセロジエニクス・インコーポレイテツド １，３−ビス−（置換フェニル）−２−プロペン−１−オン類およびｖｃａｍ−１媒介障害を治療するためのそれらの使用
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
ATE346929T1 (de) * 2001-02-07 2006-12-15 Ca Nat Research Council Methode zur herstellung von pflanzensamen mit verändertem fibergehalt und veränderter samenschale
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
ATE403426T1 (de) 2002-02-07 2008-08-15 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
WO2005097098A2 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of ppr delta agonists for treating demyelinating diseases
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
US20080286234A1 (en) * 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases
KR101760139B1 (ko) 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
US20100239528A1 (en) 2007-07-20 2010-09-23 Stem Cell Therapeutics Corp. Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta
WO2009073146A2 (en) * 2007-11-29 2009-06-11 Celgene Corporation Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
RS66784B9 (sr) 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017132769A (ja) * 2011-02-18 2017-08-03 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化

Also Published As

Publication number Publication date
US20160166687A1 (en) 2016-06-16
JP2017132769A (ja) 2017-08-03
US11246873B2 (en) 2022-02-15
US9592288B2 (en) 2017-03-14
DK2675893T3 (en) 2019-04-15
US10493080B2 (en) 2019-12-03
US20140038949A1 (en) 2014-02-06
US20170136029A1 (en) 2017-05-18
ES2716865T3 (es) 2019-06-17
EP3502236B1 (en) 2023-08-23
EP2675893B1 (en) 2019-01-09
JP2020040981A (ja) 2020-03-19
US20200390780A1 (en) 2020-12-17
EP2675893A1 (en) 2013-12-25
EP3502236A1 (en) 2019-06-26
US10660899B2 (en) 2020-05-26
EP2675893A4 (en) 2014-07-16
JP2014506583A (ja) 2014-03-17
WO2012112933A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
JP6133790B2 (ja) ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CN111789956B (zh) 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒
KR20230152844A (ko) 질환을 치료하기 위한 5ht 작용제
EP3485882A1 (en) Compositions for the treatment of pervasive development disorders
KR20180121983A (ko) Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
Gonzalez-Cabrera et al. S1P1 receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis
CA3041358A1 (en) Treatment for progressive multiple sclerosis
TWI729290B (zh) 治療疼痛的藥物組合物
EP3773556A1 (en) Compositions and methods for increasing remyelination
WO2016138099A1 (en) Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US9271987B2 (en) Methods and compositions for treating Alzheimer's disease
CN113811304A (zh) 2-苯基-6-(1h-咪唑-1-基)喹唑啉用于治疗神经退行性疾病，优选阿尔茨海默病的用途
JP2008531710A (ja) 神経変性疾患の調節
HK40010393A (en) Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
HK40010393B (en) Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US20230220037A1 (en) Novel use
EP4554577A1 (en) Novel use
Blom et al. Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy
WO2025240566A1 (en) Small molecule steroid receptor coactivator stimulators for use in repairing tissue
Marques IL-10 protects the cerebral microcirculation from spirochetal injury
Mullan Modulation ofthe phospholipase A2 pathway as a therapeutic
VENLAFAXINE DRUGS AND THE BRAIN
HK1195745B (zh) 用於抑制化疗引起的副作用的药物治疗以及相关药物组合物、诊断试剂、筛选技术和试剂盒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170420

R150 Certificate of patent or registration of utility model

Ref document number: 6133790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees